CVE:NAC - National Access Cannabis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.79 +0.03 (+3.95 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseC$0.79
Today's RangeC$0.76 - C$0.80
52-Week RangeC$0.10 - C$1.20
Volume304,390 shs
Average Volume915,181 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
National Access Clinic Corp., through its subsidiary National Access Canada Corporation, owns and operates clinics in Canada. It provides cannabinoid educational services; and medical cannabis treatments for patients through a network of physicians and health professionals. The company was formerly known as National Access Cannabis Corp. and changed its name to National Access Clinic Corp. in August 2017. National Access Clinic Corp. was incorporated in 2014 and is headquartered in Ottawa, Canada.

Receive NAC News and Ratings via Email

Sign-up to receive the latest news and ratings for NAC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange CVE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCVE:NAC
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares129,843,000
Market CapC$0.00

National Access Cannabis (CVE:NAC) Frequently Asked Questions

What is National Access Cannabis' stock symbol?

National Access Cannabis trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NAC."

What is the consensus analysts' recommendation for National Access Cannabis?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for National Access Cannabis in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are National Access Cannabis' key executives?

National Access Cannabis' management team includes the folowing people:
  • Mark Goliger, Chief Exec. Officer
  • Mr. Connor Cruise, Chief Financial Officer
  • Mr. Michael John Saliken, Corp. Sec.
  • Mr. John Gillis, Consultant

Has National Access Cannabis been receiving favorable news coverage?

News headlines about NAC stock have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. National Access Cannabis earned a news sentiment score of 0.10 on Accern's scale. They also assigned media stories about the company an impact score of 45.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of National Access Cannabis?

Shares of NAC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is National Access Cannabis' stock price today?

One share of NAC stock can currently be purchased for approximately C$0.79.


MarketBeat Community Rating for National Access Cannabis (CVE NAC)

Community Ranking:  1.2 out of 5 (star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  12
MarketBeat's community ratings are surveys of what our community members think about National Access Cannabis and other stocks. Vote "Outperform" if you believe NAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.